Table 1.
Baseline characteristics of patients related to the first anti-TNF used.
| Variable | Whole cohort (N = 473) | Intravenous infliximab (IVi group) (N = 330) | Subcutaneous anti-TNF (SCi group) (N = 143) | p |
|---|---|---|---|---|
| Female gender (%) | 224 (47) | 161 (49) | 63 (44) | 0.37 |
| Smoking status (%) | 0.40 | |||
| Active | 34 (8) | 28 (9) | 9 (6) | |
| Former | 121 (28) | 86 (26) | 45 (32) | |
| Never | 281 (64) | 216 (65) | 89 (62) | |
| Extensive colitis (%) | 279 (59) | 194 (59) | 85 (59) | 0.92 |
| Age at diagnosis, median (range) | 35 (7–79) | 36 (7–79) | 33 (15–74) | 0.02 |
| Age at the beginning of the first anti-TNF, mean (standard deviation) | 43 (14) | 44 (14) | 42 (15) | 0.17 |
| Time from diagnosis to treatment (months), median (range) | 45 (0–433) | 46 (0–433) | 42 (0–378) | 0.04 |
| Concomitant immunosuppressant treatment (%) | 258 (54) | 184 (56) | 74 (52) | 0.42 |
| Partial Mayo score, median (range) | 6 (0–9) | 6 (0–9) | 6 (0–9) | 0.04 |
| Moderate/severe partial Mayo score (%) | 327 (77) | 266 (81) | 99 (69) | 0.009 |
| Moderate/severe endoscopic Mayo subscore (%) | 326 (94) | 310 (94) | 132 (93) | 0.64 |
| Dose escalation (%) | 202 (43) | 146 (44) | 74 (52) | 0.31 |
| Treatment duration (weeks), median (range) | 32 (0–463) | 46 (0–463) | 17 (0–191) | <0.001 |
| Reason for discontinuation (%) | <0.001 | |||
| Adverse events | 110 (23) | 102 (31) | 8 (6) | |
| Primary failure | 164 (35) | 69 (21) | 95 (66) | |
| Loss of response | 171 (36) | 133 (40) | 38 (27) | |
| Other | 28 (6) | 26 (8) | 2 (1) |
Bold and italic characters within the Tables are used to highlight statistically significant results.